New possibilities for treatment of erectile dysfunction in men with type 2 diabetes

Abstract

More than 50 percent of diabetes patients suffer from erectile dysfunction (ED). Sexual dysfunction may be due to metabolic, vascular, neurological, endocrine, psychological causes or be associated with side effects of pharmacotherapy. A history of erectile dysfunction should be a regular part of medical check-up. The first line treatment in majority of patients with ED are phosphodiesterase 5 (PDE5) inhibitors. The new, highly selective medicine of this group is avanafil — a drug with rapid onset of action and high efficacy in patients with diabetes.